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OBJECTIVES We assessed the incremental long-term prognostic value of myocardial viability in surgically
revascularized (CABG) patients with left ventricular (LV) dysfunction.
BACKGROUND Clinical factors, medical therapy, the degree of LV dysfunction, and stress-induced ischemia
may affect the relative prognostic value of myocardial viability.
METHODS Patients with coronary disease and ventricular dysfunction (mean ejection fraction 33% by
echocardiography, 25% by angiography) were studied with dobutamine echocardiography.
Follow-up (mean 4.9 years) was obtained in 95 patients (85% triple-vessel disease) who
underwent CABG.
RESULTS The use of angiotensin-converting enzyme inhibitors, advanced heart failure, rest, low- and
peak-dose wall motion scores were univariate predictors of cardiac death. The extent of
contractile reserve and ischemia were not predictive. Low-dose score was the strongest
multivariate predictor of death (p  0.001, hazard ratio 6.7). A biphasic response predicted
better survival (p  0.045, hazard ratio 0.5). Five-year survival was better in those with
extensive (low-dose score 2.00) versus intermediate (score 2.00 to 2.49) amounts of viable
myocardium (p 0.019). Patients with the least viability (score2.5) had the worst outcome
(p 0.0001 vs. those with low-dose score2.00; p 0.05 vs. those with score 2.00 to 2.49).
In stepwise multivariate analysis, low-dose score added incremental prognostic value (p 
0.024) to clinical information and rest score.
CONCLUSIONS Low-dose score, representing the extent of viable myocardium, has incremental prognostic
value as a predictor of long-term outcome in CABG patients with LV dysfunction. (J Am
Coll Cardiol 2003;42:2099–105) © 2003 by the American College of Cardiology Foundation
Patients with left ventricular (LV) dysfunction and ad-
vanced coronary artery disease (CAD) who have viable
myocardium have better survival with revascularization
compared with medical therapy (1–12). Less is known about
the importance of myocardial viability to outcome within
patient cohorts who are revascularized. The results of prior
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studies suggest that revascularized patients without viable
myocardium have relatively low short-term mortality (4). In
general, prior studies have treated viability as a binary
variable, identifying patients as “nonviable” or “viable” based
on certain threshold values (13). As a result, less is known
about the impact of the extent of viable myocardium on the
prognosis of revascularized patients. Additionally, the long-
term impact of viability in revascularized patients is un-
known because, in most studies, follow-up has been limited
to two to three years (4). Investigation of the prognostic
importance of the extent of viable myocardium may help to
determine which patients derive the greatest survival benefit
from revascularization.
Previous studies have also not assessed the overall impact of
clinical factors, the degree of resting LV dysfunction, the extent
of ischemia, and the completeness of revascularization on the
prognostic value of viability in revascularized patients. In the
clinical arena, assessment of the patients’ history, medical
regimen, and resting function constitute the initial steps in risk
stratification. An evaluation for viable myocardium may follow,
and the prognostic information from this assessment is added
to the preexisting information.
The purpose of this investigation was to determine if the
presence and extent of viable myocardium influences long-
term prognosis in revascularized patients with LV dysfunc-
tion. We used several different criteria for viability to
determine which, if any, would be predictive of outcome.
We also sought to determine if the extent of viable myo-
cardium added incremental prognostic value to assessment
of clinical factors, the degree of resting dysfunction, the
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extent and severity of CAD, the extent of ischemia, and the
completeness of revascularization. Patients undergoing cor-
onary artery bypass grafting (CABG) were selected because
in these subjects viability may have a greater impact on
outcome compared with those who have percutaneous
revascularization because of the greater potential benefit
from more complete and long-lasting revascularization.
METHODS
Patient selection. The study group was selected from
patients with LV dysfunction (4 segments with resting
wall motion abnormalities) who underwent low and peak-
dose dobutamine echocardiography (DobE) between April
1991 and December 1998 at Indiana University hospitals.
Of 618 subjects with LV dysfunction evaluated during this
time period, 111 (18%) had CABG within five months of
DobE. Thirteen patients who had DobE within one week
after myocardial infarction were excluded. One patient who
did not have complete low-dose imaging was excluded, and
two patients who had ischemic events before undergoing
CABG were also excluded. The 95 remaining patients
comprised the study population. The investigation was
approved by the institutional review board, and informed
consent was obtained from all subjects.
Dobutamine echocardiography. Dobutamine was admin-
istered beginning at a dose of 5 g/kg/min for 3 min
followed by 10 g/kg/min for 3 min. Thereafter, the dose
was increased by 10 g/kg/min increments every 2 to 3 min
to a peak-dose of 50 g/kg/min. End points for dobutamine
infusion were the same as described in a previous study (12).
Echocardiograms were recorded and digitally stored at rest,
at the end of the 5 g/kg/min and 10 g/kg/min stages, and
at peak dose.
Echocardiographic analysis. Echocardiograms were ana-
lyzed by at least one investigator blinded to the clinical,
angiographic, and stress testing data. Wall motion and
thickening were assessed in 16 segments using a 6-grade
scoring system: 1  normal at rest, hyperkinetic with
dobutamine; 2  mildly hypokinetic with 5 mm inward
systolic motion; 2.5  severely hypokinetic with minimal
inward motion and wall thickening; 3  akinetic with
absence of inward motion and wall thickening; 4  dyski-
netic with paradoxical outward motion; 5  aneurysmal
with diastolic thinning (7 mm thickness).
When a disparity existed between wall motion and
thickening of an individual segment, regional function was
graded on the basis of wall thickening. Wall motion scores
at rest, at 10 g/kg/min (designated as low dose), and at
peak dose were obtained by dividing the sum of individual
segment scores by the number of segments scored.
A blinded observer measured ejection fraction (EF) using
the apical four-chamber view and Simpson’s method.
Previous studies have identified patients with viable
myocardium based on the presence of contractile reserve,
the improvement of wall thickening, and motion with
low-dose dobutamine (9–11,14). In this study, several
measures of viable myocardium used in prior studies were
included. Improvement in wall motion score from rest to
low dose of 0.20, and a biphasic response, were included
as measures of viability (9,15). The percent of myocardium
with contractile reserve at low dose was also determined.
This was defined as the number of segments with improved
wall motion scores at 10 g/kg/min divided by the number
of segments scored at this dose  100%. The proportion of
patients with contractile reserve in at least 25% of ventric-
ular myocardium was also determined (9,16).
Additionally, the percent of ischemic myocardium was
assessed. This was defined as the number of segments that
had worsening of wall motion at any stage of the test divided
by the number of segments scored at peak dose  100%.
Segments with worsening of wall motion from a score of 3
(akinetic) to 4 (dyskinetic) were not considered ischemic.
Interobserver variability. Agreement between two blinded
observers for the presence of contractile reserve was deter-
mined. In 20 patients, the resting and low-dose wall motion
scores were compared between blinded interpretations and
the clinical (unblinded interpretations) made by a stress
echocardiography expert at the time of performance of
DobE to determine if assessment of viability by blinded
readers was similar to that of clinical readers.
Follow-up. Seventy-two of 95 patients in the study had
been referred for evaluation of viable myocardium. These
subjects were prospectively followed. Retrospective
follow-up was obtained in 23 additional patients who met
the inclusion criteria for this study. Patients were contacted
by telephone for follow-up. In cases of hospital readmission
or death, medical records were obtained for documentation.
Cardiac death was the end point of the study. It was defined
as death due to intractable heart failure (CHF), myocardial
infarction, ventricular arrhythmia, or sudden death within
1 h of symptom onset without an obvious noncardiac cause.
Statistical analysis. Cox proportional hazards model was
used to identify univariate predictors of cardiac death with a
p value 0.05 considered statistically significant. Multivar-
iate analysis was conducted using all variables with p values
0.10 on univariate analysis. Step-wise multivariate analysis
was performed using all clinical, angiographic, and echocar-
diographic variables with p  0.10 on univariate analysis.
Receiver operator characteristic curve analysis was used to
determine potentially useful threshold values of echocardio-
graphic variables for derivation of survival curves. Kaplan-
Meier survival curves were constructed using five-year
Abbreviations and Acronyms
ACEI  angiotensin-converting enzyme inhibitor
CABG  coronary artery bypass grafting
CAD  coronary artery disease
CHF  congestive heart failure
DobE  dobutamine echocardiography
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follow-up data and complete follow-up data. The curves
were compared using the log-rank test. Linear regression
was used to compare wall motion scores between blinded
and clinical observers. Statistical analysis was performed
with SPSS version 11.0 for Windows (SPSS Inc., Chicago,
Illinois).
RESULTS
Patient population. Forty-one (43%) of 95 patients pre-
sented with worsening CHF, and 30 (32%) presented with
worsening angina. The remaining 24 patients had stable
symptoms or were asymptomatic.
The primary indication for performance of DobE was
assessment of viability and ischemia in 72 subjects. In the
remaining 23 subjects, 14 were studied for evaluation of
worsening angina or CHF, and 9 were studied for preop-
erative risk stratification before noncardiac surgery.
The mean age of the patients was 60  9 years. There
were 73 men (77%) and 22 women. Thirty-six patients
(38%) had diabetes, and 31 (33%) had class III or IV CHF.
Of the 95 patients, 51 (54%) were receiving angiotensin-
converting enzyme inhibitors (ACEI), and 33 (35%) were
receiving beta-blockers. The mean resting EF was 33 
10% by echocardiography and 25  8% by nuclear or
contrast angiography. The average extent of akinetic myo-
cardium without contractile reserve was 24%. Triple-vessel
disease (disease defined by 50% diameter stenosis) was
present in 85%, and two-vessel disease in 15%.
Follow-up. Follow-up was obtained in all patients for a
mean of 4.9  2.9 years. Coronary artery bypass grafting
was performed 25  34 days after echocardiography. Re-
vascularization of all significantly diseased vessels was per-
formed in 75% of patients, and 88% had at least one internal
mammary graft. Six patients had concomitant procedures
(LV aneurysm resection  2 patients; aortic valve replace-
ment  1 patient; aortic valve repair  1 patient; mitral
valve repair  2 patients). Cardiac deaths occurred in 36
patients (38%), and 10 patients had noncardiac death.
There were two perioperative deaths (2.1%). One subject
who had aneurysmectomy could not be weaned from car-
diopulmonary bypass. The other subject had death due to
uncontrollable ventricular arrhythmias. Both subjects had
viable myocardium by criteria used in prior studies. The
remaining 93 subjects were included in the analysis of
factors predicting long-term outcome. Patients with non-
cardiac death were analyzed in the “survivors” group with
their follow-up terminating at their date of death.
Univariate clinical and echocardiographic predictors of
outcome. The clinical characteristics of survivors and patients
with cardiac death during long-term follow-up are compared
in Table 1. Advanced (class III or IV) CHF predicted cardiac
death (p 0.022); ACEI use was more frequent in those who
died (p  0.040). Angiotensin-converting enzyme inhibitor
use was associated with worsening CHF at presentation (kappa
 0.24, p 0.021). There was a trend towards higher cardiac
mortality in men compared with women (p  0.097) and a
trend towards lower mortality in those receiving beta-blockers
(p  0.081).
Echocardiographic parameters in survivors and patients who
had cardiac death are compared in Table 2. Resting wall
motion score was a significant predictor of outcome, but EF
was not. With low-dose dobutamine, only low-dose score was
a significant predictor (p 0.001). There was a trend towards
a greater reduction in wall motion score from rest to low dose
in survivors compared with those who died (p 0.094). With
high-dose dobutamine, peak-dose wall motion score was the
only significant predictor. There was a trend towards a higher
frequency of a biphasic response in survivors compared with
those with cardiac death (p  0.092).
Table 3 shows that angiographic and revascularization
parameters were similar in survivors and those who had cardiac
death, and there were no significant predictors of outcome.
Multivariate analysis. Variables included in multivariate
analysis were CHF class; the use of ACEI; gender; beta-
blocker therapy; resting-, low-, and peak-dose scores;




(n  34) p Value Hazard Ratio
Age 59.5  8.9 61.1  9.7 0.171
Male gender 40 (68%) 31 (91%) 0.097 2.7 (0.83–10.5)
Hypertension 38 (64%) 23 (68%) 0.739
Diabetes 20 (34%) 15 (44%) 0.268
Hypercholesterolemia 33 (57%) 15 (44%) 0.452
Smoking 37 (63%) 28 (82%) 0.131
Family history of CAD 29 (51%) 15 (44%) 0.598
CHF class III or IV 16 (27%) 14 (41%) 0.022 2.3 (1.1–4.7)
Angina 42 (72%) 19 (56%) 0.152
Dyspnea 33 (57%) 23 (68%) 0.443
Prior bypass grafting 10 (16%) 6 (17%) 0.827
ACEI 28 (48%) 22 (65%) 0.040 2.1 (1.0–4.3)
Beta-blockers 25 (43%) 8 (24%) 0.081 0.5 (0.2–1.1)
Ca channel blockers 23 (40%) 9 (27%) 0.456
Nitrates 45 (78%) 24 (71%) 0.216
ACEI  angiotensin-converting enzyme inhibitor; CAD  coronary artery disease; CHF  congestive heart failure.
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change in score from rest to low-dose, and a biphasic
response. Low-dose score was the most important indepen-
dent predictor of cardiac death with a p value of 0.001.
The hazard ratio for low-dose score was 6.7 (2.8 to 15.8). A
biphasic response was an independent predictor of survival
(p  0.045) with a hazard ratio of 0.5 (0.2 to 0.99).
Survival analysis using low-dose scores. Receiver opera-
tor characteristic curve analysis demonstrated that the op-
timal threshold value of low-dose score for prediction of
cardiac death was 1.95. In previous studies, wall motion
score values of 2.00 and 2.50 have been found to be useful
thresholds for identification of high-risk patients (12,17).
For the purposes of this study, patients were assigned to
three groups based on low-dose score (group 1 with exten-
sive viable myocardium, score 2.00; group 2 with inter-
mediate viability, score 2.0 to 2.49; group 3 with limited
viability, score 2.5). The frequency of cardiac death was
24% (13/55) in group 1, 48% (14/29) in group 2, and 82%
(9/11) in group 3 (p 0.028 group 1 vs. 2; p 0.079 group
2 vs. 3). The annual cardiac mortality was 21% in group 3
for the first 3 years of follow-up.
Figure 1 shows survival curves at five years of follow-up
and for the complete duration of the study with all 95
patients included in the analysis. At five years, there was
significantly better survival in group 1 (extensive viability)
compared with group 2 (p  0.019) and group 3 (0.0001).
There was a trend towards improved survival in group 2
compared with group 3 (p  0.053).
Eight of 10 noncardiac deaths in the study population
occurred in group 1, and a substantial proportion of patients
in this group were censored after five years. Over the
complete duration of the study, there was a trend towards
better survival in group 1 versus group 2 (p  0.104). Both
groups 1 and 2 had better survival than patients with limited
viability in group 3 (p  0.0001 vs. group 1; p  0.0074 vs.
group 2).
Incremental value of low-dose score. The incremental
value of low-dose score was tested in a stepwise multivariate
analysis (Fig. 2). Clinical variables used in the first step were
CHF class, the use of ACEI, the use of beta-blockers, and
gender. In the second step, resting wall score added incre-
mental value to clinical parameters (p 0.003). In the third




(34) p Value Hazard Ratio
Stress hemodynamics
Peak dose (g/kg/min) 39  11 37  12 0.290
Peak heart rate (beats/min) 123  22 119  26 0.294
Peak systolic pressure (mm Hg) 134  25 130  27 0.496
Resting function
Rest EF (angiography, nuclear) 0.27  0.09 24  0.08 0.357
Rest EF (echocardiography) 0.33  0.11 0.32  0.10 0.955
Rest wall score 1.95  0.36 2.27  0.39 0.001 4.7 (1.9–12)
Low-dose echocardiography
Low-dose EF 0.39  0.11 0.39  0.10 0.581
Low-dose wall score 1.81  0.36 2.20  0.38 0.001 6.4 (2.6–16)
Rest to low change in score 0.14  0.19 0.7  0.22 0.094 0.2 (0.5–1.3)
0.20 decrease in score 21 (36%) 7 (21%) 0.177
Contractile reserve 25% of LV* 21 (36%) 10 (29%) 0.547
% Myocardium improve low dose 19  14 16  17 0.318
Peak dose echocardiography
Peak wall score 1.83  0.42 2.22  0.40 0.001 3.5 (1.6–7.6)
Presence of ischemia 43 (73%) 27 (79%) 0.933
% Ischemic myocardium 16  14 19  15 0.726
Biphasic response 31 (53%) 14 (41%) 0.092 0.6 (0.3–1.1)
*Improvement of wall motion with low dose in 25% or more of myocardium with rest wall motion abnormalities.
EF  ejection fraction; LV  left ventricle.





Three-vessel disease 49 (83%) 30 (88%) 0.741
50% stenosis LAD 57 (97%) 33 (97%) 0.932
% Diameter stenosis of LAD 80  26% 79  23% 0.876
Number of bypass grafts 3.6  1.0 3.8  1.2 0.850
Internal mammary graft 54 (92%) 30 (88%) 0.838
Complete revascularization* 46 (78%) 25 (74%) 0.349
Three or more bypass grafts 51 (88%) 28 (83%) 0.799
*Complete revascularization was defined as bypass grafting to all vessels with 50% diameter stenosis.
LAD  left anterior descending artery.
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step, low-dose score added incremental prognostic value to
the combination of clinical variables and rest score (p 
0.024). In this step, the inclusion of change in score from
rest to low-dose did not improve the prognostic value of
low-dose score alone. In the final step, peak-dose score and
a biphasic response provided no additional prognostic value.
Interobserver variability in wall motion scores. The in-
terobserver agreement between two blinded observers for
myocardium with contractile reserve was 89%. Linear re-
gression was used to compare clinical and blinded assess-
ments for resting wall motion score and low-dose score. The
correlation coefficient was 0.94 for resting score and 0.87 for
low-dose score. There was 95% agreement between clinical
and blinded readings for assignment of patients to the three
groups with extensive, intermediate, and limited viability.
DISCUSSION
This investigation showed that: 1) low-dose wall motion
score, reflecting the extent of viable myocardium, was the
best predictor of five-year outcome; 2) low-dose score
enabled classification of patients into high, intermediate,
and low-risk groups for cardiac death; 3) except for a
biphasic response, measures of contractile reserve shown in
prior studies to be predictors of short-term outcome were
not predictive of long-term outcome; 4) low-dose score
added incremental prognostic value to clinical factors, and
assessment of resting function; and 5) ischemia did not have
additional prognostic value.
Short- and long-term prognostic value of viability:
implications for selection of patients for surgical revas-
cularization. Patients with the least amount of viable
myocardium (group 3) did very poorly in spite of revascu-
larization with 63% dying within three years. As discussed
in a recent editorial, there is relatively limited information
on the optimal management (medical therapy vs. revascu-
larization) of patients with limited viable myocardium (13).
The results of previous studies have shown no adverse effects
of revascularization in this group. A recent meta-analysis
found an annual mortality of 7.7% in revascularized patients
and 6.2% in medically treated patients with limited viability
Figure 1. Survival of the three groups of patients with extensive (group 1), intermediate (group 2), and limited (group 3) myocardial viability based on
low-dose wall motion scores. The two patients with perioperative deaths are included. Log-rank p values comparing survival among the three groups at five
years and for the complete duration of the study are shown at the bottom of the figure. At five years, survival of group 1 was better than group 2, and there
was a trend towards improved survival in group 2 compared with group 3. For the complete duration of the study, there was a trend towards improved
survival in group 1 versus group 2. Survival of group 3 remained worse than groups 1 and 2.
Figure 2. Results of stepwise multivariate analysis. Resting wall score
added incremental prognostic value to clinical variables. Low-dose score
added incremental prognostic value to the combination of clinical variables
and rest score. In this step, the inclusion of change in score from rest to
low-dose did not improve on the chi-square using low-dose score alone. In
the final step, peak-dose score and a biphasic response provided no
additional prognostic value. ACEI  angiotensin-converting enzyme
inhibitor; CHF  congestive heart failure.
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(p  0.23) (4). Our results indicate that there is a subset of
patients with very limited viability in whom surgical revas-
cularization is associated with a very poor prognosis.
In this investigation, the presence of extensive viable
myocardium (group 1, low-dose score 2.00) conferred a
prognostic advantage over those with intermediate viability
(group 2) lasting at least five years. Beyond five years, the
groups with extensive and intermediate viability maintained
better survival compared with those with limited viability.
In previous studies with mixed patient populations un-
dergoing percutaneous or surgical revascularization, the
prognostic benefit of contractile reserve has been shown to
last for at least three years after revascularization (10,11).
The results of our study indicated that there is extended
prognostic benefit of viable myocardium in surgically revas-
cularized patients. The completeness of revascularization
may have contributed to the long-term benefit of viability in
this study. In the Coronary Artery Surgery registry, out-
comes in patients with LV dysfunction with 3 grafts was
improved compared with those with fewer grafts (18). In
our study, nearly all patients had three or more grafts.
Nearly all patients also had at least one arterial graft. The
importance of arterial conduits to outcome in patients with
significant viable myocardium is uncertain (19).
Incremental prognostic value of myocardial viability. In
clinical practice, selection of high-risk patients for CABG is
a process that takes into consideration multiple clinical
factors, the degree of resting dysfunction, the presence and
extent of inducible ischemia, and the extent of coronary
disease, in addition to information on myocardial viability.
The results of our study indicated that assessment of
viability adds incremental long-term prognostic informa-
tion. To date, information documenting the incremental
prognostic value of viability has been limited. Pasquet and
colleagues (20) have shown that contractile reserve adds
prognostic value to clinical factors in predicting outcome.
Medications were not included in their analysis. Their
results showed that, after adjustment for diabetes and the
extent of disease, contractile reserve remained predictive of
three-year survival in revascularized patients.
Indicators of viability: contractile reserve versus low-
dose score. In contrast with the results of previous studies,
contractile reserve was a weak predictor of outcome (9–11,
14,16). The reasons for the stronger predictive ability of
low-dose wall motion score compared with that for contrac-
tile reserve are unclear. Improvement in the prognosis of
patients with LV dysfunction may result from postrevascu-
larization improvement in function of viable myocardium.
Meluzin et al. (14) and Bax et al. (16) demonstrated that
patients who had contractile reserve and improvement of
EF with revascularization had lower rates of total cardiac
events in two years of follow-up. However, there were no
significant differences in survival between patients with and
without significant contractile reserve because of the low
number of deaths in both studies.
An investigation by Samady et al. (21) called into
question the mechanism for improvement in prognosis of
revascularized patients with LV dysfunction. In his study,
outcomes were similar in revascularized patients with and
without improvement in systolic function. Factors other
than improvement in systolic function may account for
some of the prognostic benefit of revascularization. Revas-
cularization may reduce the incidence of sudden death and
the size of future infarction, outcomes that may be unrelated
to the presence of contractile reserve (22,23).
Low-dose wall motion scores incorporate information on
the functional status of all regions of the myocardium.
Dysfunctional regions with contractile reserve, nonviable
regions without response to dobutamine, and normal re-
gions all contribute to the overall wall motion score.
Revascularization of normal regions may relieve ischemia
and contribute to better outcome. Revascularization of
regions without contractile reserve may still be beneficial by
preserving some viable cells and preventing adverse ventric-
ular remodeling. By incorporating information on the func-
tional status of all regions of the LV, low-dose wall motion
score may provide comprehensive prognostic information.
In this study, the use of low-dose score also permitted
assessment of viability as a continuous variable and im-
proved risk stratification over the simple classification of
patients as viable or nonviable. The use of low-dose score is
similar to employment of a viability index by Pagley et al.
(24). They assessed perfusion of each LV segment using
single photon emission computed tomography thallium
images, and an average perfusion score for each patient was
determined. Patients with higher viability scores (more
normal perfusion) had better survival with revascularization
than those with lower scores.
Prognostic value of stress-induced ischemia. In this
study, the presence and extent of ischemia did not add
prognostic value. The extent of ischemia was limited in both
survivors and those who died, perhaps because both groups
had more extensive amounts of nonviable myocardium than
in populations enrolled in previous studies.
The results of limited studies suggest that the extent of
preoperative ischemia may not have significant impact on
the outcome of revascularized patients. The survival of
revascularized patients with ischemia in a study by Smart et
al. (25) was excellent, regardless of the extent of ischemia.
Pasquet et al. (20) found that dobutamine-induced ischemia
did not predict the outcome of patients within the revascu-
larized group. Our results are similar and suggest that, in
patients with relatively limited ischemia, myocardial viabil-
ity is a more important factor. The relative completeness of
revascularization in our study may have also played a role in
limiting the prognostic impact of ischemia.
Study limitations. Patients were included from 1991 to
1998, a protracted period of time during which significant
changes in medical therapy have taken place. Fewer patients
in our study were receiving ACEI and beta-blockers than
may be expected for a study initiated more recently. How-
ever, the frequency of ACEI use in our study (54%) was
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comparable to that for Medicare patients (55%) treated for
CHF in the mid-1990s (26). The frequency of beta-blocker
use in our study was also low (35%) but very similar to rates
(30% to 35%) reported by the National Registry of Myo-
cardial Infarction in patients treated for infarction compli-
cated by CHF between the years of 1994 and 2000 (27).
Angiotensin-converting enzyme inhibitor use was unex-
pectedly associated with higher cardiac mortality. There was
a significant association of ACEI use with worsening CHF
at presentation, suggesting that ACEI use was another
marker for the degree of CHF.
Revascularization was considered complete if all ob-
structed vessels were grafted. No postoperative assessment
of perfusion or stress testing was performed.
A highly select patient population was enrolled. The
results of this study are applicable to those with extensive
CAD and advanced LV dysfunction who have CABG and
may not be applicable to those undergoing percutaneous
revascularization or to those treated medically.
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